1 INDIA RECORDS WORLD’S HIGHEST ONE-DAY SURGE IN COVID CASES WWW.BLOOMBERG.COM PUBLISHED:2021/04/22      2 AUSTRALIAN GOVERNMENT TEARS UP VICTORIA'S BELT AND ROAD AGREEMENT WITH CHINA, ANGERING BEIJING WWW.CNN.COM PUBLISHED:2021/04/22      3 CLIMATE CHANGE: US SURPRISES SUMMIT WITH ‘BOLD' EMISSIONS TARGET WWW.BBC.COM PUBLISHED:2021/04/22      4 MONGOLIA RECORDS 1,328 NEW COVID-19 CASES, FIVE DEATHS WWW.MONTSAME.MN PUBLISHED:2021/04/22      5 JUWAI IQI EXPANDS GLOBAL FOOTPRINT VIA PARTNERSHIP WITH MONGOLIA’S REAL ESTATE PORTAL OLY.MN AND TOP LOCAL AGENT RE/MAX MONGOLIA WWW.PRWEB.COM PUBLISHED:2021/04/22      6 MONGOLIA OFFERS JOB SUPPORT LOANS FOR COVID-19 PANDEMIC WWW.XINHUANET.COM PUBLISHED:2021/04/22      7 SPECIAL DEPARTURE FLIGHTS FOR FOREIGN CITIZENS IN MONGOLIA AFFECTED BY COVID-19-RELATED TRAVEL RESTRICTIONS WWW.MN.USEMBASSY.GOV  PUBLISHED:2021/04/22      8 GOVERNMENT OF MONGOLIA TO RAISE COUNTERCLAIM REGARDING OYU TOLGOI TAX DISPUTE WWW.MONTSAME.MN PUBLISHED:2021/04/22      9 SEEKING TO UNSEAT AUSTRALIA, MONGOLIA'S GIANT COAL MINE PLANS $700 MLN BOND WWW.REUTERS.COM PUBLISHED:2021/04/21      10 PM ADDRESSES AT BOAO FORUM FOR ASIA ANNUAL CONFERENCE 2021 WWW.MONTSAME.MN PUBLISHED:2021/04/21      SXCOAL: НИЙЛҮҮЛЭЛТ БУУРСНААР КОКСЖИХ НҮҮРСНИЙ ҮНЭ 22 САРЫН ДЭЭД ТҮВШИНД ХҮРЧ ӨСӨВ WWW.BLOOMBERGTV.MN НИЙТЭЛСЭН:2021/04/22     "50,400 ТУН АСТРАЗЕНЕКА ВАКЦИН ХҮЛЭЭН АВЛАА. СИНОФАРМЫН 900,000 ТУН ВАКЦИНЫГ ОЙРЫН ӨДРҮҮДЭД АВЧИРНА" WWW.IKON.MN НИЙТЭЛСЭН:2021/04/22     ЗГ: 8,000 ГАРУЙ ААН, ИРГЭН 560 ТЭРБУМ ТӨГРӨГИЙН ЗЭЭЛ АВААД БАЙНА WWW.GOGO.MN НИЙТЭЛСЭН:2021/04/22     “ОЮУТОЛГОЙ”-Н ЗЭСИЙН БАЯЖМАЛЫН ЭКСПОРТ СЭРГЭВ WWW.NEWS.MN НИЙТЭЛСЭН:2021/04/22     БАНКНЫ САЛБАРЫН ЖЕНДЕРИЙН ТАЛААРХ СТАТИСТИКИЙГ ТАНИЛЦУУЛАВ WWW.MONTSAME.MN НИЙТЭЛСЭН:2021/04/22     ТАТВАРЫН ОРЛОГО 78.1 ХУВИЙН ГҮЙЦЭТГЭЛТЭЙ БАЙНА WWW.MONTSAME.MN НИЙТЭЛСЭН:2021/04/22     ГУРВАН ХУВИЙН ХҮҮТЭЙ ЗЭЭЛИЙГ 8092 ХҮН АВЧЭЭ WWW.EAGLE.MN НИЙТЭЛСЭН:2021/04/22     ШҮЛСНЭЭС КОРОНАВИРУС ИЛРҮҮЛЭХ ОНОШЛУУРЫГ ИРЭХ ДАВАА ГАРАГААС ХЭРЭГЛЭНЭ WWW.EAGLE.MN НИЙТЭЛСЭН:2021/04/22     НӨАТ-ЫН БУЦААН ОЛГОЛТЫГ ИРГЭДИЙН ДАНСАНД ШИЛЖҮҮЛЖ ЭХЭЛЛЭЭ WWW.GOGO.MN НИЙТЭЛСЭН:2021/04/21     ЭКСПОРТ 100 САЯ ГАРУЙ АМ.ДОЛЛАРООР ӨСЖЭЭ WWW.MONTSAME.MN НИЙТЭЛСЭН:2021/04/21    

Johnson & Johnson's one-shot COVID-19 vaccine effective and safe: FDA staff www.reuters.com

(Reuters) - Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.
Slideshow ( 2 images )
The FDA’s panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA usually does and has authorized vaccines from Pfizer and Moderna.
J&J said in documents submitted to the FDA that its data suggested its vaccine was effective at preventing asymptomatic infections. It said that in a preliminary analysis of its trial, it found 16 cases of asymptomatic cases in the placebo group versus two in the vaccine group, or an 88% efficacy rate.
While asymptomatic infection was not the primary goal of the trial, which studied the vaccine’s ability to stop moderate to severe COVID-19, the reduction of asymptomatic cases implies the shot can also cut transmission of the disease.
J&J’s vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month.
Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease.
The vaccine was effective in reducing the risk of COVID-19 and preventing PCR-test confirmed COVID-19 at least 14 days after vaccination, the FDA said in its briefing documents.
Fourteen days after injection, only two vaccine recipients developed COVID-19 severe enough to need medical intervention, compared with 14 in the placebo group. After 28 days, no vaccine recipients developed COVID severe enough to require medical intervention whereas seven in the placebo group did.
Three vaccine recipients had severe side effects in the trial that were likely related to the vaccine, but the FDA said its analysis did not raise any specific safety concerns that would preclude issuance of an emergency use authorization.
The FDA said the most common solicited adverse reactions were injection site pain at 48.6%, headache at 39%, fatigue at 38.2% and myalgia at 33.2%. Other side effects included a fever in 9% of participants and a high fever in 0.2% of those who received the vaccine.
The regulator said one case of pericarditis, a heart disease, may have been caused by the vaccine. It said cases of a rare disorder, Guillain-Barre Syndrome, were unlikely to be related to the shot though data was insufficient to determine whether or not the vaccine had caused these side effects.
J&J had not previously released details of its clinical trial data beyond efficacy rates.
Reporting by Manas Mishra in Bengaluru; Mike Erman, Caroline Humer and Rebecca Spalding; Editing by Bernard Orr and David Clarke


Published Date:2021-02-24